SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Tadsamillionaire11/24/2006 12:37:26 PM
   of 255
 
Aradigm Announces the Results of the AERx HCQ Asthma Phase 2a Study
Aradigm Corporation (PINKSHEETS: ARDM) today announced that the results of the Phase 2a clinical trial program of inhaled hydroxychloroquine (HCQ) as treatment for patients with moderate-persistent asthma, conducted on behalf of and funded by APT Pharmaceuticals ("APT"), did not meet the pre-specified clinical efficacy endpoints. No serious adverse events were reported either related to the drug or Aradigm's AERx delivery system.

Both APT and Aradigm will be continuing the data analysis, in order to decide whether they will pursue additional investigations with inhaled HCQ.

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, pulmonary hypertension, asthma, inhalation anthrax infections and smoking cessation.

In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. Novo Nordisk also remains a substantial shareholder and investor in Aradigm.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext